Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152566 | 0.88 | F10 (0.69) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL2434397 | 0.84 | F10 (0.56) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL799808 | 0.82 | RAB9A (0.63) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL890674 | 0.82 | NPC1 (0.70) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL30338953 | 0.82 | NPC1 (0.70) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL24073685 | 0.81 | NPC1 (0.69) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL30142733 | 0.81 | NPC1 (0.69) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL3151641 | 0.80 | SORT1 (0.61) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL13315106 | 0.79 | SMN1; SMN2 (0.87) | F10RAB9ANPC1ALOX15HTT | |
| SCHEMBL24074627 | 0.79 | NPC1 (0.66) | F10RAB9ANPC1ALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542529-B1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | LLC PHARMADIALL (RU) | 2019-09-04 | — | — | EP | disclosed |
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PLAUR, PLAU, UTS2R | F10 9/4885RAB9A 1722/4885NPC1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.